Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Medical Genetics

Building Your Care Team and Long-Term Monitoring

At a Glance

Alpha-mannosidosis can affect several body systems, so long-term care is coordinated by a metabolic geneticist and other specialists. Personalized monitoring may cover hearing, vision, heart and lung health, development, mental health, and a planned transition to adult care.

Managing alpha-mannosidosis is not something one doctor can do alone. Because the condition affects multiple systems—from hearing and bone health to the immune system and the brain—it requires a “multidisciplinary” care team [1]. This team works together to monitor health, coordinate therapies, and adjust treatments over a lifetime.

Your Care Team Roster

A specialized metabolic geneticist or biochemical geneticist usually leads medical care [1]. However, daily functioning depends heavily on a broader team:

  • Genetic Counselor: To discuss family recurrence risks and reproductive options.
  • Audiologist and ENT: To monitor and manage hearing loss (sensorineural or conductive) and ear infections [2][3].
  • Physical, Occupational, and Speech-Language Therapists: To maximize mobility, daily living skills, and communication.
  • Neurologist: To track brain health, motor skills, and ataxia [4].
  • Ophthalmologist: To monitor the retina and optic nerve [5].
  • Pulmonologist and Cardiologist: To evaluate lung and heart function over time [6][7].
  • Orthopedist: To manage skeletal changes or joint stiffness [8].
  • Psychiatrist or Psychologist: To support mental health and behavior [8].
  • Social Worker: To assist with school/workplace accommodations, disability benefits, and care coordination.

A Tailored Surveillance Blueprint

International consensus guidelines recommend a comprehensive set of baseline assessments at the time of diagnosis [1]. However, the exact choice and frequency of follow-up tests must be tailored to age, symptoms, cooperation, and treatment status.

  1. Hearing and Vision: Regular audiometry is vital [9]. Eye exams should include dilated evaluations; specialized imaging like OCT (Optical Coherence Tomography) and ERG (Electroretinography) may be used depending on age and symptoms [5][10].
  2. Heart and Lungs: Monitoring may involve pulmonary function tests (PFTs) and echocardiography to check for issues like valve disease [6][7].
  3. Developmental Tracking: Periodic neuropsychological testing helps track learning progress, adaptive skills, and cognitive trajectories [11][12].
  4. Mental and Behavioral Health: Psychiatric symptoms (like severe anxiety, hallucinations, or mood changes) can emerge, particularly in adolescence and adulthood [13]. If severe agitation, loss of safety, or self-harm thoughts occur, seek urgent emergency psychiatric assessment.

Research and Registries

If participating in enzyme replacement therapy (ERT), you may be invited to join a patient registry, such as the SPARKLE registry [14].

  • What it is: Registries collect “real-world” data on the safety, biochemical markers, and long-term effectiveness of treatments [14].
  • Your Choice: Participation is strictly voluntary, requires informed consent regarding data privacy, and is not a requirement to receive standard care.

Transitioning to Adult Care

Transitioning from a pediatric to an adult care team is a critical process. Because many adult specialists are unfamiliar with alpha-mannosidosis, this must be a carefully coordinated “handover” [15][1].

  • Start Early: Transition discussions should ideally begin in the early teenage years [15].
  • Coordinate Care: The pediatric geneticist should provide a comprehensive medical summary and a “surveillance roadmap” to the new adult team [1].
  • Support for Independence: Transition planning must also cover supported decision-making, independent living skills, vocational support, and reproductive planning for the future [11][15].

Common questions in this guide

Which specialists are usually involved in alpha-mannosidosis care?
A metabolic or biochemical geneticist often leads care, with referrals based on the person’s needs. The team may include hearing and ear specialists, therapists, neurology, eye, heart and lung, orthopedic, mental-health, and social-work professionals.
What tests are used for long-term alpha-mannosidosis monitoring?
Monitoring may include regular hearing tests, dilated eye examinations, pulmonary function tests, heart ultrasound, and periodic neuropsychological testing. The schedule and need for specialized eye tests such as OCT or ERG depend on age, symptoms, ability to cooperate, and treatment status.
What mental or behavioral changes need urgent attention?
Anxiety, hallucinations, mood changes, or other psychiatric symptoms can occur, especially during adolescence or adulthood. Severe agitation, loss of safety, or thoughts of self-harm require urgent emergency psychiatric assessment.
Is joining the SPARKLE registry required to receive treatment?
Participation in SPARKLE or another patient registry is voluntary and is not required to receive standard care. Before joining, people should receive information about the registry, give informed consent, and understand how their health data will be protected and used.
When should transition to adult alpha-mannosidosis care begin?
Transition planning should begin in the early teenage years rather than waiting until the transfer is imminent. The pediatric team can prepare a detailed medical summary and monitoring plan while addressing decision-making, independent living, education, work, and reproductive planning.
How can we keep alpha-mannosidosis specialists coordinated?
Families can ask the metabolic genetics team to identify a primary care coordinator who tracks referrals, test results, and communication among specialists. Keeping a current medical summary, surveillance roadmap, and centralized record or patient portal can also reduce gaps in care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Who is the primary 'care coordinator' on our team who will ensure all these different specialists are communicating with each other?
  2. 2.Can we review the recommended baseline assessments from the current consensus guidelines and tailor a surveillance plan for our specific needs?
  3. 3.What specific psychiatric or behavioral signs should we watch for, and what is the emergency plan if severe symptoms arise?
  4. 4.How do we access genetic counseling, physical therapy, or speech-language support?
  5. 5.Is participation in a disease registry (like SPARKLE) available to us, and what does the consent and data privacy process involve?
  6. 6.At what age should we start the formal 'handover' process to adult specialists to ensure there is no gap in treatments or care?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Monitoring and integrated care coordination of patients with alpha-mannosidosis: A global Delphi consensus study.

    Guffon N, Burton BK, Ficicioglu C, et al.

    Molecular genetics and metabolism 2024; (142(4)):108519 doi:10.1016/j.ymgme.2024.108519.

    PMID: 39024860
  2. 2

    Audiological and radiological study of eight polish patients with alpha-mannosidosis.

    Iwanicka-Pronicka K, Guzek A, Sarnecki J, Tylki-Szymańska A

    International journal of pediatric otorhinolaryngology 2023; (169()):111556 doi:10.1016/j.ijporl.2023.111556.

    PMID: 37099947
  3. 3

    Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group.

    Guffon N, Tylki-Szymanska A, Borgwardt L, et al.

    Molecular genetics and metabolism 2019; (126(4)):470-474 doi:10.1016/j.ymgme.2019.01.024.

    PMID: 30792122
  4. 4

    White matter alteration and cerebellar atrophy are hallmarks of brain MRI in alpha-mannosidosis.

    Majovska J, Nestrasil I, Paulson A, et al.

    Molecular genetics and metabolism 2021; (132(3)):189-197 doi:10.1016/j.ymgme.2020.11.008.

    PMID: 33317989
  5. 5

    Early-Onset Retinal Dystrophy in Alpha-Mannosidosis: A Case Report.

    Almhmoudi F, Bamusa A, Alrashid A, et al.

    Case reports in ophthalmology 2026; (17(1)):471-478 doi:10.1159/000551949.

    PMID: 42282242
  6. 6

    Comprehensive cardiopulmonary assessment in α mannosidosis.

    Nir V, Bentur L, Tal G, et al.

    Pediatric pulmonology 2020; (55(9)):2348-2353 doi:10.1002/ppul.24864.

    PMID: 32445542
  7. 7

    Long-term clinical evaluation of patients with alpha-mannosidosis - A multicenter study.

    Köse E, Kasapkara ÇS, İnci A, et al.

    European journal of medical genetics 2024; (68()):104927 doi:10.1016/j.ejmg.2024.104927.

    PMID: 38382588
  8. 8

    Long-term outcome of a cohort of Italian patients affected with alpha-Mannosidosis.

    Bertolini A, Rigoldi M, Cianflone A, et al.

    Clinical dysmorphology 2024; (33(1)):1-8 doi:10.1097/MCD.0000000000000474.

    PMID: 37791705
  9. 9

    Long-term outcome of patients with alpha-mannosidosis - A single center study.

    Lipiński P, Różdżyńska-Świątkowska A, Iwanicka-Pronicka K, et al.

    Molecular genetics and metabolism reports 2022; (30()):100826 doi:10.1016/j.ymgmr.2021.100826.

    PMID: 35242565
  10. 10

    Retinal and optic nerve degeneration in α-mannosidosis.

    Matlach J, Zindel T, Amraoui Y, et al.

    Orphanet journal of rare diseases 2018; (13(1)):88 doi:10.1186/s13023-018-0829-z.

    PMID: 29859105
  11. 11

    Cognitive profile and activities of daily living: 35 patients with alpha-mannosidosis.

    Borgwardt L, Thuesen AM, Olsen KJ, et al.

    Journal of inherited metabolic disease 2015; (38(6)):1119-27 doi:10.1007/s10545-015-9862-4.

    PMID: 26016802
  12. 12

    Intellectual functioning in alpha-mannosidosis.

    Cathey SS, Sarasua SM, Simensen R, et al.

    JIMD reports 2019; (50(1)):44-49 doi:10.1002/jmd2.12073.

    PMID: 31741826
  13. 13

    Retrospective Study of Clinical and Genetic Profiles of Alpha-Mannosidosis Patients From the UAE.

    Saad AK, Al-Hammadi T, Al-Ameri S, et al.

    JIMD reports 2025; (66(2)):e70001 doi:10.1002/jmd2.70001.

    PMID: 39926434
  14. 14

    The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis.

    Hennermann JB, Guffon N, Cattaneo F, et al.

    Orphanet journal of rare diseases 2020; (15(1)):271 doi:10.1186/s13023-020-01549-8.

    PMID: 32993743
  15. 15

    Caregivers' and Physicians' Perspectives on Alpha-Mannosidosis: A Report from Italy.

    Verrecchia E, Sicignano LL, Massaro MG, et al.

    Advances in therapy 2021; (38(1)):1-10 doi:10.1007/s12325-020-01574-w.

    PMID: 33231860

This page is for informational purposes only and does not constitute medical advice. A metabolic geneticist and your care team should tailor alpha-mannosidosis monitoring, referrals, and emergency plans to your needs.

Get notified when new evidence is published on Alpha-mannosidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.